14-3-3η: A Critical Mass of Data
A recent systematic literature review describes a substantive body of evidence for 14-3-3η’s clinically important role along the whole continuum of rheumatoid arthritis and autoimmune patient care.
Key Statements:
- 14-3-3η helps to assess the veracity of the diagnosis and severity of early RA.
- Can be combined with existing markers to stratify patients to more effective treatments.
- 14-3-3ƞ is a welcome addition for a rheumatologist’s diagnostic and treatment strategy in RA.
Source: The role of 14-3-3 η as a biomarker in rheumatoid arthritis
Rheumatology and Immunology Research, 2021
How RA Joint Involvement “Spreads”
New findings: 14-3-3η drives joint damage through promoting invadosome formation.
Key Findings:
- Consistent with previous findings 14-3-3ƞ is upregulated in a diseased state and is differentially expressed in RA vs OA.
- In RA, fibroblast-like synoviocytes (FLS) are the most common contributors to joint destruction. 14-3-3ƞ drives FLS transformation and contributes dose dependently to joint damage progression.
- 14-3-3ƞ regulates SNAIL production and sequesters FOXO providing new mechanistic insights into the regulation of joint degradation.
Source: 14-3-3η Promotes Invadosome Formation via the FOXO3–Snail Axis in Rheumatoid Arthritis Fibroblast-like Synoviocytes,
International Journal of Molecular Science, 2021
Arthritis-Health:
14-3-3η Blood Test for diagnosing RA
Arthritis-Health, a trusted publication of Veritas Health which is produced and blind peer-reviewed by licensed health professionals, lists 14-3-3η as the newest biological marker of RA.
Source: Blood Tests to Help Diagnose Rheumatoid Arthritis (RA),
Arthritis-Health.com
| For a list of 14-3-3η publications visit our publications page. |
The 14-3-3η Blood Test is Available at:
About Augurex
Augurex is a commercial stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test which detects the 14-3-3η protein, available as JOINTstat® in Canada, is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte specific reagents to detect 14-3-3η are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. SPINEstat® expands Augurex’s biomarker-informed diagnostic autoimmune portfolio into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which if untreated can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn and X.